Docket Number:12A-980915
Inventor:Te-Chang Lee, Tsann-Long Su
IP Status:TW I548410、US 8,703,957 B2
Abstract:
The market of DNA alkylating agents has been increased in recent years since several powerful antitumor alkylating drugs (such as Temodar and Eloxatin) entered into the cancer treatment market. The current invention discloses the combination of 3a-aza-cyclopenta[a]indenes (bifunctional alkylating agents) and ATO displays significant inhibition against drug resistant tumor xenografts in nude mice and has high potential for clinical chemotherapy application.
Fields of Application:
Cancer chemotherapy.
Advantages when compared to the existing technologies:
We have recently studied the combination therapeutic effects of various DNA alkylating agents (including nitrosoureas, cisplatin, N-mustanrds and 3a-aza-cyclopenta[a]indenes) with ATO (inhibitor of DNA repair). We found that combining 3a-aza-cyclopenta[a]indenes (e. g., BO-1012) with ATO exhibit the most synergistic effect against human large cell lung carcinoma or bladder carcinoma resistant to cisplatin in animal with low toxicity. Both cancer patients are difficult to be cured. The new invention disclose that the combination of 3a-aza-cyclopenta[a]indenes (e. g., BO-1012) and ATO exhibits potent therapeutic efficacy against inherited or acquired resistant tumor xenografts both in vitro and in vivo. These new findings revealed that the therapeutic effect of combining BO-1012 with ATO is superior to single drug therapy.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
